Armata Capital Surpluse from 2010 to 2025

ARMP Stock  USD 1.95  0.04  2.01%   
Armata Pharmaceuticals Capital Surpluse yearly trend continues to be relatively stable with very little volatility. Capital Surpluse is likely to drop to about 245.6 M. During the period from 2010 to 2025, Armata Pharmaceuticals Capital Surpluse destribution of quarterly values had range of 242.5 M from its regression line and mean deviation of  73,614,018. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
247.9 M
Current Value
245.6 M
Quarterly Volatility
81.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 3.2 M or Selling General Administrative of 10 M, as well as many indicators such as Price To Sales Ratio of 28.2, Dividend Yield of 0.0175 or Days Sales Outstanding of 256. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Armata Pharmaceuticals Correlation against competitors.
To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Latest Armata Pharmaceuticals' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Armata Pharmaceuticals over the last few years. It is Armata Pharmaceuticals' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Armata Capital Surpluse Regression Statistics

Arithmetic Mean318,836,206
Geometric Mean307,921,445
Coefficient Of Variation25.45
Mean Deviation73,614,018
Median375,177,000
Standard Deviation81,142,291
Sample Variance6584.1T
Range242.5M
R-Value(0.70)
Mean Square Error3566.1T
R-Squared0.49
Significance0
Slope(11,984,791)
Total Sum of Squares98761.1T

Armata Capital Surpluse History

2025245.6 M
2024247.9 M
2022275.5 M
2021228 M
2020198.4 M
2019172 M
2018414.5 M

About Armata Pharmaceuticals Financial Statements

Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse247.9 M245.6 M

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.